The aforementioned therapeutically beneficial targets regulated by μ-21 include both well-characterized protein effectors in CRC, such as MAD2L1, and proteins with limited prior association with CRC pathogenesis, including eIF3F, NPM1, LAMB1, RPL31, and RPA1. This evidence concerns the gene MAD2L1 and colorectal carcinoma.